J&J looks to toss its SGLT2 hat in the ring for two types of heart failure
In the last year, two SGLT2 inhibitors — initially developed to treat diabetes — have snagged approvals in the heart failure space. Now Johnson & Johnson is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
